- Home
- RY vs SNY Comparison
RY vs SNY Comparison
Compare RY & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RY
- SNY
- Stock Information
- Founded
- RY 1864
- SNY 1994
- Country
- RY Canada
- SNY France
- Employees
- RY N/A
- SNY N/A
- Industry
- RY
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- RY
- SNY Health Care
- Exchange
- RY Nasdaq
- SNY Nasdaq
- Market Cap
- RY 159.6B
- SNY 123.6B
- IPO Year
- RY N/A
- SNY N/A
- Fundamental
- Price
- RY $117.75
- SNY $53.63
- Analyst Decision
- RY Strong Buy
- SNY Buy
- Analyst Count
- RY 2
- SNY 2
- Target Price
- RY $156.50
- SNY $62.50
- AVG Volume (30 Days)
- RY 1.7M
- SNY 3.6M
- Earning Date
- RY 05-29-2025
- SNY 04-24-2025
- Dividend Yield
- RY 3.49%
- SNY 3.08%
- EPS Growth
- RY 16.08
- SNY 39.56
- EPS
- RY 8.49
- SNY 5.45
- Revenue
- RY $39,472,538,730.00
- SNY $48,817,552,946.00
- Revenue This Year
- RY $22.14
- SNY $5.35
- Revenue Next Year
- RY $3.42
- SNY $6.69
- P/E Ratio
- RY $13.85
- SNY $18.87
- Revenue Growth
- RY 16.96
- SNY N/A
- 52 Week Low
- RY $96.52
- SNY $45.80
- 52 Week High
- RY $128.05
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- RY 57.53
- SNY 50.20
- Support Level
- RY $116.34
- SNY $50.46
- Resistance Level
- RY $119.86
- SNY $51.64
- Average True Range (ATR)
- RY 3.02
- SNY 1.60
- MACD
- RY 0.66
- SNY 0.15
- Stochastic Oscillator
- RY 84.67
- SNY 65.92
About RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with over CAD 2 trillion in assets. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.